Business Context and Reporting Period
This Form 8-K was filed by Conversion Labs, Inc. (noted as Lifemd, Inc. in metadata) on April 25, 2019. The filing reports the entry into a material definitive agreement and the completion of an asset acquisition involving the company's subsidiary, Conversion Labs PR, LLC ("CVLB PR").
Key Financial Metrics
The filing text does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The transaction was structured as an equity exchange rather than a cash transaction.
- Transaction Type: Purchase of remaining membership interests in a subsidiary.
- Consideration: Cancellation of potential restricted stock/options and issuance of 5,000,000 shares of restricted common stock.
- Ownership Change: Company ownership of CVLB PR increased from approximately 78.17% to 100%.
Material Changes
On April 25, 2019, Conversion Labs, Inc. acquired the remaining 21.83333% membership interest of CVLB PR from Related Parties (including the CEO and CTO). This transaction resulted in the Company becoming the sole member of CVLB PR. Concurrently, the Operating Agreement of CVLB PR was amended to reflect this change in ownership.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclosures regarding the transaction.
- Compensatory Arrangements: The issuance of 5,000,000 shares (2,500,000 to each executive) was made in exchange for the cancellation of prior potential issuances related to employment. Additional restricted stock may be issued based on milestones enumerated in the Membership Interest Purchase Agreement (MIPA).
- Regulatory Exemption: The securities were issued in reliance on Section 4(a)(2) of the Securities Act as a private transaction to accredited investors.
Investor Verification Checklist
- Verify the exact terms and milestones for potential additional stock issuances in the attached MIPA (Exhibit 10.1).
- Confirm the valuation of the 5,000,000 shares issued and the impact on existing shareholder dilution.
- Review the Amended Operating Agreement (Exhibit 10.2) for any new governance structures or obligations imposed on the subsidiary.
- Check subsequent filings for the vesting schedule of the restricted stock issued to the CEO and CTO.